Comparative study of change of HbA1c with voglibose and teneligliptin on ongoing metformin monotherapy

Abstract

Background: Metformin is a biguanide used as first line treatment of type 2 diabetes mellitus. When Metformin alone is unable to control glycaemic status properly then additional drug needs to be added. Some of the additional drugs reduce primarily fasting blood sugar (FBS) and some reduce post prandial blood sugar (PPBS). Voglibose and Teneligliptin are primarily capable of reducing PPBS. Overall hyperglycaemia is also controlled by these drugs. In this background the present study was planned for comparative study of Voglibose and Teneligliptin to reduce HbA1c ongoing Metformin monotherapy. Materials & Methods: It was a hospital based longitudinal interventional study among patients attending General Medicine Outpatient Department (OPD) of a Medical College, East Medinipur, West Bengal with uncontrolled hyperglycemia and whose HbA1c was above 7 but up to 10% and PPBS above 200mg/dl. One group of patients was given voglibose 0.3mg TDS and another group of patients were given teneligliptin 20mg BD in addition to previous dose of metformin. After 12 weeks of starting additional drug again HbA1c level was assessed for each patient. Results: It was found that mean HbA1c level at the beginning was 8.89% for voglibose group and 8.83% for teneligliptin group. There was no significant difference between these two. After 12 weeks of therapy the mean HbA1c level of voglibose group was significantly higher than teneligliptin group. However both groups showed significant reduction of HbA1c as compared to starting. Conclusion: The study highlights the ability to reduce HbA1c is more with teneligliptin 20mg BD than voglibose 0.3mg TDS.